ErVimmune
Latest round
- Series A
Last raised
- Jan 2026
Total raised
- $21M
Investors
- 2
About ErVimmune
Founded in 2019 and headquartered in Lyon, France, ErVimmune develops immunotherapy solutions for cancer treatment.ErVimmune specializes in the development of innovative immunotherapies, focusing on cancer vaccines and T cell-based therapies that specifically target cold tumors. Utilizing a proprietary, AI-driven target discovery platform, the company identifies non-conventional antigens derived from human endogenous retroviruses (HERVs). This unique approach enables ErVimmune to create therapies aimed at addressing critical unmet medical needs in cancer treatment, particularly by utilizing accurate non-mutated tumor epitopes shared across various patients and cancer types.ErVimmune's revenue model is largely sustained through strategic partnerships and collaborations with research institutions and healthcare providers, aimed at advancing clinical development programs for their cancer therapies. These collaborations often lead to licensing agreements and research partnerships, facilitating the integration of their technologies into broader clinical frameworks. The pricing of flagship products, including their lead cancer vaccine candidate, will be based on therapeutic value and the outcomes from associated research. The funds will aid in the enhancement of their cancer therapies and the expansion of their market presence. The company aims to introduce new products targeting specific cancer indications and is also focusing on geographical expansion within Europe and North America by 2026.
Who invested in ErVimmune
2 investors across 2 rounds
See all investors in ErVimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ErVimmune
Who invested in ErVimmune?
ErVimmune has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ErVimmune raised?
ErVimmune has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ErVimmune last raise money?
ErVimmune's most recent round on record is a Series A, in Jan 2026.
What does ErVimmune do?
Founded in 2019 and headquartered in Lyon, France, ErVimmune develops immunotherapy solutions for cancer treatment.
Where is ErVimmune headquartered?
ErVimmune is headquartered in Lyon, France.
Which VCs invest in companies like ErVimmune?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at ErVimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ErVimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.